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Editorial: Conference Issue-2nd International Conference on 
Autoimmunity 2018; Where have we Gotten to? 
Alan Sacerdote* 
Chief, Endocrine Division, NYC Health+Hospitals/Woodhull Clinical Professor of Medicine, SUNY Downstate 
Medical Center& NYU School of Medicine, Professor of Medicine, St. George’s University, Brooklyn, New 
York, USA 
Our second annual conference was held June 20, 
2018, at New York City Health+Hospitals/Woodhull. 
Synergy Conferences partnered with Woodhull to put 
together a learning and networking experience which 
was rewarding for everyone who participated as a 
speaker, poster presenter, session chair, or audience 
member. 
I would like to extend warm thanks to the other 
members of the Scientific Committee who helped in 
suggesting lecturers for the invitation, including Dr. Gὕl 
Bahtiyar, Dr. Jocelyne Karam, and Dr. Yong Zhao. 
I would like to thank our organizers at Synergy 
Conferences/Synergy Publishing, including Ahmed 
Ullah, Organizing Secretary, Noman Pirzada, Sadaf 
Idrees Khan without whose hard work, infrastructure, 
web, and financial support the conference could not 
have taken place. 
An enormous debt of gratitude also goes to our 
Woodhull support team from the Department of Medical 
Communications: Stephanie Lugo, Patrick Ashley, and 
Ray Gibson-who did much on short notice, the 
Department of Community Affairs: Maria Hernandez, 
Andre Marie Suarez, Sammy Rodriguez, and to 
Anthony DiVittis, Associate Director for Planning and 
Public Affairs, our Executive Director, Gregory Calliste, 
our Senior Associate Director of Graduate Medical 
Education, Chermain Cross, our Department of 
Medicine Program Director, Susan Grossman and our 
chief medical residents, Kevin Singh and Pawel 
Szurnicki for arranging for our medical residents to 
attend, our department administrator, Bibiana Soto and 
our executive associates: Yolanda Dawson, Mary 
Hayes, Jinette Maldonado, Jovanie Santos, and Gail 
Charles for organizing the on-site registration and  
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assisting with catering arrangements. We should also 
like to thank our Food/Nutrition Dept. for their breakfast 
and morning coffee break arrangements. No 
conference is possible without speakers/presenters 
and session chairs and we were fortunate to have a 
wonderful group of speakers/presenters from 
administrative, clergy, political, clinical, translational, 
epidemiologic, and basic science backgrounds sharing 
their unique perspectives.  
Mr. Gregory Calliste, Woodhull’s Executive Director, 
opened the conference with an eloquent greeting to all 
those attending the conference, stressing the impact of 
autoimmune disorders on the Brooklyn community.  
The inspiring invocation prayer was offered by 
Woodhull Chaplain, Sister Lilia Njoku. 
Our Chief Guest, Brooklyn Borough President, Eric 
Adams, inaugurated the conference, emphasizing the 
impact of autoimmune disease on the people of 
Brooklyn and sharing his inspirational personal 
experience of controlling his Type 2 diabetes through 
use of a low calorie, vegan diet, and a regular exercise 
program, shedding considerable weight in the process.  
The first academic session was chaired by Dr. Yong 
Zhao from the Department of Biomedical Research at 
Hackensack University Medical Center. 
Dr. Harold Lebovitz, Emeritus Professor of Medicine 
and former Chief of the Endocrine Division at SUNY 
Downstate Medical Center, kicked off our scientific 
program with a lecture entitled Autoimmune 
Polyglandular Syndrome: a Merger of Endocrinology 
and Immunology in which he updated us on 
Autoimmune Polyglandular Syndrome (APS) 1, a rare, 
autosomal recessive disorder in which there are 
mutations in the autoimmune regulator (AIRE) gene 
with early onset and clinical findings of 
hypoparathyroidism, mucocutaneous candidiasis, and 
adrenal insufficiency, APS 2, a polygenic disorder, 
unlike APS 1, which is monogenic, involving mutations 
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in genes in the major histocompatibility locus, typically 
with an adult clinical onset and often presenting with 
Type 1 diabetes, Addison’s disease, autoimmune 
thyroid disorders and primary hypoparathyroidism as 
well as other autoimmune disorders, and X-linked 
immunodysregulation, polyendocrinopathy, and 
enteropathy (IPEX)-a very rare FOX-P3 disorder 
presenting in infancy with neonatal Type 1 diabetes, 
autoimmune enteropathy, eczema, and other 
autoimmune disorders. 
The next speaker in the scientific program was Dr. 
MaryAnn Banerji, Professor of Medicine and current 
Chief of the Division of Endocrinology and Metabolism 
at SUNY Downstate Medical Center who spoke to us 
about Autoimmunity in Type 2 Diabetes, a disorder 
that, traditionally, has not been thought of as 
autoimmune. She discussed the fact that “Flatbush” 
diabetes often presents with diabetic ketoacidosis, 
much like in Type 1 diabetic patients, however, most of 
the Flatbush diabetic patients do not develop 
circulating antibodies to insulin or islet cell antigens and 
have a clinical course typical of type 2 diabetics, often 
not requiring the use of exogenous insulin after initial 
treatment. “Typical” Type 2 diabetic patients, initially 
well-controlled with lifestyle measures alone or in 
combination with oral agents may quickly progress to 
insulin dependence and develop antibodies to islet 
antigens, suggesting that they have subsequently 
developed Type 1 diabetes or latent autoimmune 
diabetes of adults (LADA), although many LADA 
patients never require insulin. Many patients with Type 
2 diabetes with or without circulating antibodies against 
insulin or islet cell antigens demonstrate T cell 
reactivity to islet cell antigens. Chronic, low-grade 
inflammation participates in the pathogenesis of type 2 
diabetes with a build-up of innate immune cells in 
adipose and other metabolic tissues resulting in the 
increased release of inflammatory cytokines, such as 
TNF-α and IL-1β, which cause both insulin resistance 
and autoimmune β-islet cell damage (as occurs in Type 
1 diabetes). In addition, type 2 diabetes is often 
associated with other autoimmune disorders including 
psoriasis and vitiligo. 
The second session was chaired by Dr. MaryAnn 
Banerji (previously introduced). 
After his stellar poster and lecture last year, Dr. 
Yong Zhao, from the Department of Biomedical 
Research at Hackensack University Medical Center, 
returned to this year’s conference as a member of the 
Scientific Committee and updated us on the subject of 
Stem Cell Educator Therapy and Type 1 Diabetes: 
From Bench to Clinic with some data on this therapy for 
autoimmune alopecia as well. This therapy is a closed-
loop system that moves the patient’s blood through a 
blood cell separator and then briefly co-cultures the 
patient’s lymphocytes with cord blood stem cells 
expressing autoimmune regulator (AIRE) in vitro and 
then returns the ‘educated” lymphocytes only to the 
patient resulting in durable reversal of autoimmunity; 
acting, in effect, like an artificial thymus. Key to the 
therapeutic effectiveness of this procedure is the 
presence of platelet mitochondria possessing immune 
tolerance-associated markers that allow beta islet cells 
to be reprogrammed to proliferate, with good viability 
and restoration of normal insulin production. This 
therapy may help many patients with Type 1 diabetes, 
Type 2 diabetes, and autoimmune alopecia with 
minimal invasiveness and avoid ethical and risk 
concerns associated with transplantation or use of 
embryonic stem cells. 
The third session was chaired by Dr. Alan 
Sacerdote, Chief of the Division of Endocrinology at 
NYC Health+Hospitals/Woodhull, Clinical Professor of 
Medicine at SUNY Downstate Medical Center and NYU 
School of Medicine and Professor of Medicine at St. 
George’s University. Dr. Jocelyne Karam, Director of 
the Division of Endocrinology at Maimonides Medical 
Center, Affiliate Site Program Director of the SUNY 
Downstate Endocrine Fellowship Program, as well as 
Clinical Assistant Professor of Medicine at SUNY 
Downstate Medical Center, gave a very informative 
lecture entitled Thyroid Autoimmunity and Pregnancy. 
She shared data showing that more than 12% of 
women of reproductive age have positive anti-thyroid 
peroxidase (TPO) antibodies and that the presence of 
these antibodies is associated with an increased risk 
for poor pregnancy-associated outcomes including, 
spontaneous abortion, pre-term delivery, subclinical 
hypothyroidism, and post-partum thyroiditis. More 
limited data suggest that low dose l-thyroxine treatment 
of euthyroid anti-TPO ab positive pregnant women to 
achieve/maintain the serum TSH<2.5 MIU/ml reduces 
the risk for both spontaneous abortion and pre-term 
delivery and recent guidelines suggest that it be 
considered in this patient group. 
The next session was chaired by Dr. Behzad 
Dorotaj, Chief, Division of Hematology/Oncology, NYC 
Health+Hospitals/Woodhull. This session was a lecture 
on Primary Biliary Cholangitis given by Dr. Nora 
Bergasa, Chief of the Hepatology Clinic at NYC 
Health+Hospitals/Woodhull, Director of the Dept. of 
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Medicine, NYC Health+Hospitals/Metropolitan. This 
disorder, previously known as primary biliary cirrhosis 
is an autoimmune disorder characterized by chronic, 
non-suppurative, progressive inflammation of septal 
and interlobular intrahepatic bile ducts, often 
culminating in cirrhosis and liver failure. Liver function 
tests are consistent with cholestasis. Characteristic 
symptoms are pruritus and fatigue. The research of Dr. 
Bergasa and others supports increased opiodergic tone 
as a possible cause for the itching. Most patients have 
high titers of anti-mitochondrial antibodies and high IgM 
levels. Current treatment is primarily with 
ursodeoxycholic acid which can delay the need for liver 
transplantation, with non-responders who meet certain 
criteria being offered obeticholic acid. 
The fifth session was chaired by Dr. Marie-Alex 
Michel-Vincent, Chief of the Nephrology Division, NYC 
Health+Hospitals/Woodhull. This session was a 
fascinating lecture on the Influence of the Gut 
Microbiome on Autoimmunity presented by Dr. Maria S 
Maritato, Chief of the Infectious Disease Division, NYC 
Health+Hospitals/Woodhull and Clerkship Co-Director, 
Woodhull Medical and Mental Health Center, St. 
George’s University. In her talk, Dr. Maritato highlighted 
those autoimmune disorders which have been most 
closely associated with alterations in the gut biome. 
She explained how dysbiosis resulting from 
antimicrobial drugs, diet, and other influences in the gut 
can lead to weakening of the innate immune system via 
increasing gut permeability and exposure of the 
adaptive immune system to antigens in microbes, food, 
and other ingested materials which may be similar to 
self-antigens (molecular mimicry), resulting in an 
immune response directed against one’s self. Such 
changes may also be associated with weight gain and 
subsequent insulin resistance with increased 
inflammatory chemokine and cytokine production, 
sustaining the autoimmune response. 
The sixth session on autoimmune renal disease 
was chaired by Dr. Jocelyne Karam (previously 
introduced as a speaker). The first lecture in this 
session was given by Dr. Paul Byssainthe, Attending 
Physician in the Nephrology Division at NYC 
Health+Hospitals/Woodhull, who spoke on IgA 
Nephropathy, one of the most common autoimmune 
renal disorders. He reviewed the pathophysiology and 
varied clinical presentations of this disorder as well as 
the most up to date therapies, which include both 
immune system-targeted therapies and therapies which 
are useful in chronic kidney disease generally such as 
dietary protein/phosphorus restriction and drugs which 
block the renin-angiotensin system.  
The second lecture in this session was given  
by Dr. Marie-Alex Michel-Vincent, Chief, Division of 
Nephrology, NYC Health+Hospitals/Woodhull, who 
spoke on the myriad presentations of Lupus Nephritis, 
another of the most common autoimmune, chronic 
renal disorders, using a case-based approach. The 
presentations range from mild to those that cause end-
stage renal disease. These presentations, based on 
renal biopsies performed at Woodhull, are: mesangial 
lupus nephritis, focal lupus nephritis, diffuse 
proliferative lupus nephritis, membranous lupus 
nephritis, advanced glomerulosclerosis, crescentic 
presentation, lupus interstitial nephritis, double 
antibody disease with anti-glomerular basement 
membrane antibody, and double antibody disease with 
anti-myeloperoxidase (MPO) antibodies- antineutrophil 
cytoplasmic antibodies (ANCA). Some patients were 
very ill systemically with dramatic extra-renal 
manifestations, but with very mild renal involvement, 
while others had significant renal involvement with 
minimal or no systemic manifestations and were not 
diagnosed until renal biopsy had been performed. 
The plenary lecture session following the lunch 
break was chaired by Dr. Paul Byssainthe (previously 
introduced). The lecture, entitled Helminth 
Immunomodulation in Autoimmune Disease was 
delivered by Dr. Sara Lustigman, Head, Laboratory of 
Molecular Parasitology, Lindsley F. Kimball Research 
Institute, New York Blood Center. Here we see the 
influence of the gut macrobiome as we did with the 
microbiome in Dr. Maritato’s lecture. She began by 
reviewing the observations of many people that 
parasitic worm infections can last for many years, often 
triggering very little host immunopathology and 
generally resulting in a predominantly Th-2 host 
immune response, favoring persistence of the parasite 
within the host. This response is in contrast to the 
typical Th-1 response seen with viral infections and in 
autoimmune disorders. The “old friends” hypothesis 
suggests that this tolerance to helminth parasites exists 
because, during evolution, mammalian immune 
systems have evolved in continuous contact with these 
helminth pathogens. 
Epidemiologically, it has been observed that as 
helminth infections have been reduced through vaccine 
programs, mass anti-helminthic drug distribution, and 
improved hygienic/socioeconomic conditions there has 
been a concomitant rise in the prevalence of 
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autoimmune and allergic disease. There has recently 
been a striking inverse relationship observed between 
the prevalence of nematode infection and several 
autoimmune disorders including, T2DM, RA, and SLE. 
Public health initiatives, e.g. deworming, have been 
associated with an increased incidence of atopy. It has 
been observed that helminth-associated molecules 
may have potent regulatory effects on mammalian 
immune systems and redirecting the immune-
regulating abilities of nematode worms and their 
secretions to treat human inflammatory (including 
autoimmune) disorders is now a subject of intensifying 
research. This work ties in nicely with work by Larralde 
et al. [1] showing that in the helminthic disease, 
cysticercosis, the parasite estrogenifies the host to 
create a more hospitable environment. Subsequent 
work by the same group in Mexico [2] showed that use 
of the selective estrogen receptor modulator (SERM), 
tamoxifen, significantly reduced the parasite burden in 
mice. Later, our group successfully treated a patient 
with neurocysticercosis-induced polycystic ovarian 
syndrome (PCOS) with the SERM, raloxifene as well 
as metformin, resulting in both resolution of the PCOS 
and a decrease in her CNS parasite burden [3] as well 
as a reduction in the elevated serum level of 1, 25 
(OH)2-Vitamin D3 associated with the parasitosis. In 
addition, research is being advanced into the 
development of an immuno-stimulatory helminth-
associated molecule as an antigen-sparing adjuvant for 
the influenza vaccine to improve its effectiveness. 
The next session was chaired by Gὕl Bahtiyar, MD, 
MPH, Attending Endocrinologist, NYC 
Health+Hospitals/Woodhull, Clinical Associate 
Professor of Medicine, NYU School of Medicine, 
Associate Professor of Medicine, St. George’s 
University, and Clinical Assistant Professor of 
Medicine, SUNY Downstate Medical Center. The 
session speaker was Nanette Alexander-Thomas, MD, 
FACP, FACR who spoke to us about State of the Art 
Treatment of Rheumatoid Arthritis (RA) involving the 
early use of disease-modifying medications including 
methotrexate, TNF-α blockade, and monoclonal 
antibodies directed against inflammatory cytokines and 
chemokines. Though cure remains elusive, the 
appropriate use of these agents has dramatically 
changed the outlook for RA patients from the dismal 
recent past, when RA was frequently a crippling, 
disease with a shortened life expectancy, to a 
manageable chronic disorder with a virtually normal life 
expectancy, much less disability, and a reasonably 
good quality of life. 
The following session was chaired by Dr. Marie-
Alex Michel-Vincent (previously introduced) and 
featured a lecture by Dr. Alan Sacerdote (previously 
introduced) entitled Non-Classic Adrenal Hyperplasia, 
Vitamin D, Insulin Resistance, and Autoimmunity. Dr. 
Sacerdote began by reviewing concepts and data from 
his lecture at last year’s meeting and highlighting 
relevant data acquired since then. Key concepts from 
this lecture include: 
• Almost all patients with autoimmune disorders 
investigated to date have non-classic adrenal 
hyperplasia (NCAH). Possible reasons for this 
are discussed in the companion article 
summarizing his lecture. 
• Both NCAH and classic CAH are characterized 
by insulin resistance (IR). 
• Hypovitaminosis D is generally present in both 
NCAH and autoimmune disorders. 
• Interventions which reduce IR, including 
metformin, thiazolidinediones, lifestyle changes, 
bariatric surgery, Vitamin D, ashwagandha, 
biotin, zinc, copper, beta-carotene, and Vitamin 
C have been reported to ameliorate NCAH and 
classic CAH clinically and biochemically as well 
as to ameliorate or prevent a number of 
autoimmune disorders. 
• Worsening and protracted Vitamin D deficiency 
has been reported to exacerbate NCAH. 
• IR and autoimmunity have much in common 
including an alteration in the gut biome to one 
that is less numerous in total number of 
organisms and less varied in terms of species 
and an increase in many pro-inflammatory 
cytokines/chemokines, lower mean serum 25-
OH-vitamin D levels compared to healthy 
controls and amelioration reported with vitamin D 
replacement. 
The next session was chaired by Alan Sacerdote 
(previously introduced). This session featured a lecture 
by Dr. Mohamed Boutjdir, Professor of Medicine at 
NYU School of Medicine and SUNY Downstate Medical 
Center and Attending Cardiologist at the New York 
Harbor Healthcare System, entitled Autoimmune 
Channelopathies as a Novel Mechanism in Cardiac 
Arrhythmias. He told us that congestive heart failure 
and coronary artery disease remain the most common 
causes of cardiac arrest. However, in 5-15% of 
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patients, there are no identifiable structural 
abnormalities present at the autopsy. In some of these 
patients mutations involving proteins within the cardiac 
ion channels have been reported (inherited 
channelopathies), however, in almost 70% of patients 
with structurally normal ion channels no responsible 
mutations have been identified. Recent evidence 
suggests that autoimmunity may be responsible for 
some of these arrhythmias. Several arrythmogenic 
antibodies targeting potassium and calcium ion 
channels in the heart have recently been identified. 
Both preclinical and clinical studies have shown that 
these antibodies can promote conduction abnormalities 
and dangerous tachyarrythmias by precipitating 
electrophysiologic changes in these channels. Most of 
the available data has involved anti-SS/Ro antibodies 
in patients with concurrent autoimmune connective 
tissue disease. It is, of course, possible that these 
antibodies, as well as any associated cellular immune 
responses, may exacerbate channel dysfunction due to 
coronary disease, heart failure, or inherited mutations 
of channel protein genes.  
The next session was the poster session wherein 5 
posters were presented by trainees, a nurse, and an 
attending surgeon related to autoimmunity and/or 
NCAH, which were as follows: Inoue T, Soni L, Bahlol 
M, Fenteany G, Bahtiyar G, Sacerdote A. Worsening 
and Prolonged Hypovitaminosis D is Associated with 
Biochemical Exacerbation of Non-classic 11-
Hydroxylase Deficiency, Sultana T, Inoue T, Gattorno 
F, Soni L, Fenteany G, Bahtiyar G, Sacerdote, initial 
Empagliflozin Use in Type 2 Diabetes is Associated 
with Remission of Adrenal Hyperandrogenism, Karen 
Simon MS, BSN, RN, Taiga Inoue, MS, MD, Gabriel 
Fenteany PhD, Gul Bahtiyar MD, MPH, Alan 
Sacerdote, MD Ashwagandha Root in the Treatment of 
Prediabetes, Christopher Albergo, MD, Galina 
Glazman, MD, Alan Scott Sacerdote, MD, FACP, A 
Novel Case of Normokalemic Thyrotoxic Periodic 
Paralysis in an Elderly Haitian Woman, Eliza Sharma, 
MD, Christine Resta, MD, Elizabeth Sedlis-Singer, MD, 
Luba Rakhlin, MD, Jocelyne Karam, MD. Amiodarone-
Induced Cure of Graves’ disease. Great interactions 
between poster presenters and other attendees were 
observed. 
Following the poster session, Dr. Alan Sacerdote 
presented, what was originally scheduled to be the 
Keynote Address of Dr. Mayris Webber of the 
Department of Epidemiology and Population Health, 
Montefiore Medical Center, Albert Einstein College of 
Medicine, and the Fire Department of the City of New 
York, Bureau of Health Services. Her topic was Post-
September 11, 2001, Incidence of Systemic 
Autoimmune Diseases in World Trade Center-Exposed 
Firefighters and Emergency Medical Service Workers. 
Dr. Webber was unable to appear in person but 
graciously furnished her PowerPoint presentation. 
Their goal was to estimate the incidence of selected 
systemic autoimmune diseases (SAIDs) in nearly 
14,000 male rescue/recovery workers enrolled in the 
New York Fire Department’s (FDNY) World Trade 
Center (WTC) Health Program and to compare this 
incidence to that of demographically similar males in 
the Rochester Epidemiology Project (REP), a 
population-based database for Olmsted County, 
Minnesota (location of the Mayo Clinic). They 
calculated the incidence for specific SAIDs (SLE, RA, 
psoriatic arthritis and others) combining SAIDs 
diagnosed between September 12, 2001, and 
September 11, 2014, and produced expected age and 
gender-specific rates based on REP rates. The 
incidence rates were stratified by the level of exposure 
to the WTC site (Ground Zero) (higher vs lower). They 
next calculated standardized incidence ratios (SIRs) 
which were the ratio of the observed number of cases 
of SAIDs in the FDNY cohort to the expected number 
of cases based on REP incidence rates. Ninety-five 
percent confidence intervals for the SIRs were then 
computed. The authors identified 97 SAID cases in the 
FDNY cohort. The overall FDNY incidence rates were 
not significantly different from the expected (REP) rates 
(SIR 0.97; 95% CI, 0.77-1.21). The lower WTC 
exposure cohort had 9.9 fewer SAID cases than 
expected, while the higher exposure cohort had 7.7 
more cases than expected. 
In interpreting these results Dr. Webber’s slides 
refer to the fact that in most published studies of 
occupational exposure, what is called ‘the healthy 
worker effect” reduces the association between 
exposure and outcome by about 20%-this is about 
what they observed in the lower exposure WTC cohort. 
The healthy worker effect takes into account that, in 
general, people who are working are somewhat 
healthier than the general population, which would 
include more ill and/or disabled people. This may be 
especially true in occupational groups such as 
firefighters and EMS workers for whom a certain level 
of physical fitness is a job requirement. The overall 
FDNY SAID incidence rate obscured differences in 
incidence according to the level of WTC site exposure 
because the higher exposure group was small.  
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Continued surveillance of this population for early 
detection of SAIDs, as well as other autoimmune 
disorders, is warranted, especially in the higher 
exposure cohort. 
The conference was concluded with inspiring 
closing remarks from our hospital’s Associate Director 
for Planning and Public Affairs, Mr. Anthony DiVittis, 
who had such an important role in coordinating the 
logistics of our conference. 
After chairing the Scientific Committees for 
Autoimmunity in 2017; Where Are We Now? and 2nd 
Conference on Autoimmunity 2018; Where Have We 
Gotten To? I shall be passing the torch to a younger, 
more energetic future chairperson. It has been a rare 
privilege to work with so many talented and dedicated 
people to make these 2 past autoimmunity conferences 
a reality. My hopes and prayers for future, even more 
successful, conferences are with my successor. 
These findings may have relevance for people and 
animals exposed to planned demolition sites as well as 
those that are terrorism or war victims 
Alan Sacerdote, July 26, 2018. 
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